This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Kristiina M. Burkhart; Craig N. Burkhart; Craig G. Burkhart, MS
Department of Medicine Medical College of Ohio 5600 Monroe St, Suite 106B Sylvania, OH 43560

Arch Dermatol. 1997;133(10):1314.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

We noted the interchange between Franz et al¹ and Downs² in recent issues of the ARCHIVES concerning the available topical scabietic agents that are currently used. However, with the Food and Drug Administration's approval of ivermectin (Stromectol, Merck & Co Inc, West Point, Pa) in November 1996, a new era of scabietic therapeutics began. Ivermectin is an anthelmintic used extensively in veterinary medicine for a wide range of nematode, insect, and acarine parasites, including Sarcoptes scabiei in animals.³ We use this drug routinely every 2 months for all the Arabian horses on our farm to control any potential parasitic infection. In fact, ivermectin is sold over-the-counter at farm supply stores, tack shops, grain elevators, and via stock catalogs for animal use. The drug has also been used in more than 6 million people for diseases, including onchocerciasis, strongyloidiasis, loiasis, bancroftian filariasis, and cutaneous larva migrans.

There already . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?